SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitwise Hyperliquid ETF - Bitwise Hyperliquid ETF

Bitwise Hyperliquid ETF

BHYP is trending as investors react to the Bitwise Hyperliquid ETF debut, with community members highlighting its role in providing direct institutional access to the Hyperliquid ecosystem. Discussions are heavily focused on the potential for unrelenting institutional buying pressure and the ongoing debate surrounding its long-term growth potential compared to other major crypto assets.

Shping takes the entire retail industry to the next level by totally disrupting how brands discover and interact with their end consumers. Shping is a robust ecosystem that connects brands to the main grocery buyer as they shop, bypassing Search Engines and Social Media giants and enabling brands to direct their marketing spend directly to the end consumer. For the first time, brands can gain control over their communication channel with the shoppers directly and are now powered to influence buying decisions of the global army of shoppers in a trillion-dollar industry.  The Shping platform is used by many global and local brands where Shping has outperformed in cost in terms of interactions and conversions compared to the top 3 three social media platforms.

SHPING

SHPING is trending as investors aggressively speculate on a potential price surge, driven by rumors of imminent AI-related developments and new exchange listings. Community members are actively debating whether this is a genuine breakout opportunity or another typical pump-and-dump cycle, with many emphasizing its low market cap and long-term utility as reasons to hold.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee ($LKNCY) is rallying as investors react to strong double-digit revenue growth and the company's first-ever $300 million share buyback program. The community is buzzing over this signal of institutional confidence, with many traders speculating that these proactive capital measures are a deliberate step toward an eventual relisting on a major U.S. exchange.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley is trending as investors digest the firm's strategic push into crypto ETFs and its role as a key player in navigating high-profile IPO activity. The community is actively debating the bank's long-term growth potential and its leadership in deal-making amid a volatile macro environment.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is seeing significant investor attention driven by strong earnings momentum and growth in its Innovative Medicine and MedTech segments, even as it navigates ongoing talc-related legal overhangs. The community is actively debating the stock's defensive rotation status versus the potential impact of long-term litigation exposure.

Willis Towers Watson Plc engages in the provision of advisory, broking, and solutions services. It operates through the following segments: Health, Wealth, and Career (HCW), Risk and Broking (R&B), and Corporate and Other. The HCW segment provides an array of advice, broking, solutions, and technology for employee benefit plans, institutional investors, compensation and career programs, and the employee experience overall. The R&B segment focuses on a broad range of risk advice, insurance brokerage, and consulting services to clients globally, ranging from small businesses to multinational corporations. The company was founded in 1828 and is headquartered in London, the United Kingdom.

Willis Towers Watson Public Limited Co

WTW is currently trending as investors monitor its organic growth recovery and margin expansion efforts following mixed reactions to recent earnings. Market participants are actively discussing the impact of AI fee compression and potential pricing tailwinds from geopolitical risks while keeping a close eye on the stock's performance relative to key support levels.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is trending due to the company's recent leadership in high-profile IPO activity and positive sentiment regarding its strong Q1 earnings performance. The community is actively discussing the stock's milestone crossing of the four-digit price level, with many traders debating its long-term growth potential and role in the current institutional market rally.

WidePoint Corp. engages in the provision of Technology Management as a Service (TMaaS). The firm is involved in providing managed services for government and commercial clients that include identity management, secure mobility managed services, telecom lifecycle management, digital billing and analytics, and Information Technology as a service (ITaaS). The company was founded on May 30, 1997 and is headquartered in Fairfax, VA.

Widepoint Corp

WidePoint is generating significant investor buzz due to the anticipation surrounding the massive DHS CWMS 3.0 contract and emerging momentum within the DoD Spiral 4 vehicle, which the community views as a potential catalyst for long-term growth. While traders are actively debating the stock's valuation versus its low-margin government contract dependencies, the community is closely watching for new SaaS contract announcements that could finally drive the profitability needed to break the stock out of its current range.

Cantor Equity Partners II, Inc. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on November 11, 2020 and is headquartered in New York, NY.

Cantor Equity Partners II Inc. - Ordinary Shares - Class A

Cantor Equity Partners II Inc

Cantor Equity Partners II is trending as investors monitor its upcoming SPAC merger with Securitize, a leading infrastructure provider for tokenized real-world assets. The community is actively discussing the platform's institutional partnerships with major players like BlackRock, while debating the valuation potential of this pure-play entry into the expanding tokenization market.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is currently navigating heightened scrutiny as reports of internal probes into private fund valuations weigh on investor sentiment. Meanwhile, the community remains divided, weighing the firm's aggressive expansion into crypto-linked financial products against broader concerns regarding private credit liquidity and ongoing regulatory investigations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Surges as Big Money Backs High-Stakes Kidney Disease Push

The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory pathways responsible for some of medicine's most difficult-to-treat diseases. Among the most closely watched areas is the complement system, a network of proteins that can trigger severe tissue damage when overactivated. With growing interest in kidney disorders and autoimmune diseases, investors are increasingly rewarding companies developing targeted therapies capable of interrupting these pathways with greater precision and fewer side effects.Shares of InflaRx N.V. ...

InflaRx N.V. (NASDAQ:IFRX) Short Interest Update

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 1,809,027 shares, a decline of 26.2% from the March 31st total of 2,452,174 shares. Approximately 3.0% of the company's stock are short...

InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday

InflaRx (NASDAQ:IFRX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-inflarx-stock...

InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer

Oppenheimer initiated coverage on InflaRx in a report on Friday. They set an "outperform" rating and a $5.00 price target on the stock...

InflaRx's (IFRX) "Buy" Rating Reaffirmed at Guggenheim

Guggenheim reiterated a "buy" rating and set a $14.00 price target on shares of InflaRx in a report on Tuesday...

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy ratin...

InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Should You Buy?

InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Still a Buy...

InflaRx N.V. (NASDAQ:IFRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One...

HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX)

InflaRx N.V. (NASDAQ:IFRX - Free Report) - Analysts at HC Wainwright issued their Q3 2026 EPS estimates for InflaRx in a research note issued on Thursday, March 19th. HC Wainwright analyst M. Keller...

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.09	--	--	N/A
Q1 '26	-$0.14	--	--	N/A
Q4 '25	-$0.16	--	--	N/A
Q3 '25	-$0.21	--	--	N/A
Q2 '25	-$0.22	-$0.24	-13.19%	MISSED

IFRX
InflaRx N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Compact View

Latest IFRX News

IFRXInflaRx N.V.